a co-development agreement on drug repositioningCo-Development Agreement • March 16th, 2016
Contract Type FiledMarch 16th, 2016The agreement has the determination to join the know-how of both companies with the aim to identify new repurposing candidates, either through internal discovery tools or through external in-licensing and co-development. The extensive network of Inorgen with academia, research institutions and biotech companies, along with the discovery tools and development activities of SOM Biotech makes a unique and promising way to accelerate new treatments from discovery to clinical stage.